Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more
Sue Desmond-Hellmann is stepping down after five years as CEO of the Bill & Melinda Gates Foundation. Before joining the foundation, she spent 14 years at Genentech Inc., where she helped develop cancer drugs Herceptin trastuzumab and Avastin bevacizumab. She then served as the first female chancellor of the University of California at San Francisco in 2009-14. Mark Suzman, the foundation's chief strategy officer and president of global policy and advocacy, will become CEO on Feb. 1.
Oncology company CStone Pharmaceuticals Co. Ltd. (HKEX:2616) hired Shirley Zhao as general manager for Greater China and head of commercial. Zhao was general manager for the China unit of Bristol-Myers Squibb Co. (NYSE:BMY), where she led the launch of Opdivo nivolumab, the first anti-PD-1 mAb to enter China’s market. CStone has five candidates in pivotal trials, including anti-PD-1 and anti-PD-L1 mAbs. ...